A specific focus of the European Commission and European Parliament is to investigate the effect potential mergers and acquisitions (M&As) will have on the state of the market.
The European Commission has released a new report on competition enforcement in the pharmaceutical sector. The report includes information on pharmaceutical competition litigation throughout Europe, and seeks to help lawmakers “strengthen the balance of pharmaceutical systems in the [European Union].”
Since 2009, the European Commission (EC) and the European Parliament (EP) have adopted 29 antitrust decisions against pharmaceutical companies. The European authorities work closely together in order to safeguard effective competition on pharmaceutical markets, and to protect patient access to affordable and innovative medicines. A specific focus of the EC and EP is to investigate the effect potential mergers and acquisitions (M&As) will have on the state of the market.
The EC has intervened in a number of mergers that were determined to potentially have led to price increases for patients. In terms of biosimilars, the EC took a specific interest in the merger of Pfizer and Hospira in 2015.
According to the report, “the Commission was concerned that the merger would do away with 1 of the 2 parallel projects to develop competing biosimilars.” This concern stemmed from the fact that, under the merger, Pfizer would take ownership of both Hospira’s infliximab biosimilar, and Pfizer’s own competing infliximab biosimilar that was being developed.
To address these concerns, the Commission produced in-depth reporting that looked into each pharmaceutical product that overlapped between the 2 companies, as well as other potential biosimilars being developed and how this merger could affect those products entering the market.
The Commission then approved the merger only after Pfizer agreed to divest certain parts of its business, such as the development and marketing of its biosimilar infliximab, as well as its sterile injectables business. In February 2016, Novartis announced that it had acquired the divested business.
The report reinforced the idea that competition authorities should remain vigilant in investigating potentially anticompetitive M&A arrangements, especially where “new practices used by companies or new trends in the industry are concerned, such as the growing relevance of biosimilars.”
Trade group Medicines for Europe, which represents the generic, biosimilar, and value-added medicines industries in Europe, praised the report, saying that the findings give valuable information on preventing delays to biosimilar and generic competition.
Said Adrian van den Hoven, director general of Medicines for Europe, in a statement, the report “shows the important role that competition rules play in the pharmaceutical sector…This is going to result in better access for patients and sustainable healthcare systems throughout Europe.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.